Alexion Pharmaceuticals Inc (NASDAQ:ALXN)

135.09
Delayed Data
As of Jul 19
 -0.56 / -0.41%
Today’s Change
102.10
Today|||52-Week Range
149.34
+12.96%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$30.2B

Company Description

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in New Haven, CT.

Contact Information

Alexion Pharmaceuticals, Inc.
100 College Street
New Haven Connecticut 06510
P:(120) 320-3272
Investor Relations:

Employees

Shareholders

Mutual fund holders56.29%
Individual stakeholders4.90%
Other institutional39.82%

Top Executives

Ludwig N. HantsonChief Executive Officer & Director
Paul J. ClancyChief Financial Officer & Executive Vice President
John J. OrloffExecutive VP & Head-Research & Development
Indrani M. FranchiniChief Compliance Officer & Executive VP
Anne-Marie LawChief Human Resource Officer & Executive VP